INOVIO(NASDAQ: INO)宣布,该公司已经在评估其新冠候选疫苗——DNA药品INO-4800的2期试验中完成了首位受试者给药。这一2期临床试验是名为INNOVATE(INovio INO-4800Vaccine Trial for Efficacy,即:INovio INO-4800疫苗有效性试验)的2/3期临床试验的一部分。试验的2期阶段将在美国17个研究中心招募约400名年龄18岁...
该公司已携手北京艾棣维欣生物技术有限公司和国际疫苗研究所(International Vaccine Institute)，分别在中国和韩国推进INO-4800的临床试验。INOVIO还与英国公共卫生部和澳大利亚联邦科学与工业研究组织(Commonwealth Scientific and Industrial Research Organization)一起评估INO-4800在几个动物挑战性模型中表现出的临床前有效性。
METHODS. We used a SARS-CoV-2 IgG ELISA and a pseudo neutralization assay to assess humoral responses, and an IFN纬 ELISpot to measure cellular responses against SARS-CoV-2 VOC in subjects immunized with the DNA vaccine, INO-4800. RESULTS. IgG binding titers were not impacted between wild-...
INOVIO近期宣布已在美国进行INO-4800 2/3期临床试验2期阶段试验中完成首批受试者给药。这项试验名为INNOVATE,即INOVIO INO-4800 Vaccine Trial for Efficacy(INNOVIO INO-4800疫苗效力试验)。 (美通社,2020年12月14日宾夕法尼亚州普利茅斯米廷)
Human Trials Planned for April; One Million Doses Expected by Year End PLYMOUTH MEETING, Pennsylvania,March 3, 2020/PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced an accelerated timeline for developing its DNA vaccine INO-4800 to address COVID-19, the respir...
Global surveillance has identified emerging SARS-CoV-2 variants of concern (VOC) associated with broadened host specificity, pathogenicity, and immune evasion to vaccine-induced immunity. Here we compared humoral and cellular responses against SARS-CoV-2
INOVIO还与Advaccine和国际疫苗研究所(International Vaccine Institute)合作,分别在中国和韩国进行INO-4800药物的临床试验研究。 除此之外,INOVIO与英国公共卫生部(PHE)和澳大利亚联邦科学与工业研究组织(CSIRO)一同在几种动物模型上进行了IN...
INOVIO is also evaluating INO-4800, a DNA vaccine candidate against COVID-19, in a Phase 2/3 clinical trial; the Phase 3 efficacy segment of which has received regulatory approvals to begin in Mexico, Braz...
INO-4800 is INOVIO's prophylactic DNA vaccine candidate against SARS-CoV-2, the novel coronavirus that causes COVID-19. INOVIO is leveraging its extensive experience with INO-4700, its DNA vaccine against another important coronavirus, th...
来源: https://www.prnewswire.com/news-releases/inovio-announces-publication-of-phase-1-data-from-its-covid-19-dna-vaccine-candidate-ino-4800-in-the-lancets-eclinicalmedicine-301198408.html